Captor Therapeutics secures USD 2 million grant for Captor Therapeutics stock

Published on 10/13/2026 at 03:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Captor posted a PLN 22.76 million loss versus PLN 20.47 million in the first half of 2026. For Captor Therapeutics stock, it means USD 2 million without dilution.

Key points in brief

Captor Therapeutics secured a USD 2 million non-dilutive grant for its NEK7 project on September 29, 2026.
The grant supports research into a brain-penetrant candidate for neurodegenerative diseases, including Parkinson's disease.
The company reported a PLN 22.76 million net loss for the first half of 2026, versus PLN 20.47 million a year earlier.
Captor Therapeutics had PLN 71.5 million in cash and investments at the end of the first half, with funding projected through the third quarter of 2027.

Captor Therapeutics, PLCPTRT00014, Illustration mit AI erstellt.

Captor Therapeutics secured a USD 2 million grant for its NEK7 project on September 29, 2026, giving Captor Therapeutics stock a concrete funding development to assess. According to Captor Therapeutics, the non-dilutive award from The Michael J. Fox Foundation will support a brain-penetrant candidate for neurodegenerative diseases, including Parkinson's disease.

What does the grant mean for funding?

The grant is material against the company's research base because it adds USD 2 million without an announced share issue or convertible debt. Captor also retains intellectual property rights connected with the NEK7 project, according to the September 29 company report.

Three milestones shape the story

The funding agreement followed a March 3, 2026 share sale of 800,000 Series Y shares at PLN 82 per share, a transaction listed by MarketScreener. On September 15, 2026, Captor reported a PLN 22.76 million net loss for the first half, compared with PLN 20.47 million in the same period a year earlier, according to MarketScreener. The September 29 grant was the latest of the three events.

What are the next dates?

Zonebourse lists November 19, 2026, as the next scheduled publication date for Captor's third-quarter results. The date matters because the first-half loss and the grant place funding duration alongside pipeline execution, rather than revenue growth, at the center of the investment case.

Cash runway reaches 2027

Captor said it held PLN 71.5 million in cash and investments at the end of the first half of 2026 and expected funding to last through the third quarter of 2027, according to Bankier. That runway gives the grant strategic value, but the reported loss shows that clinical development continues to consume capital.

The further course of trading is shown by the continuously updated real-time quote of Captor Therapeutics stock.